Member Info for Basser1

Been caught out by the TYK2 market news?

https://www.businesswire.com/news/home/20211129005192/en/Bristol-Myers-Squibb%E2%80%99s-Applications-for-Deucravacitinib-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Accepted-by-U.S.-Food-and-Drug-Administration-and-Validated-by-European-Medicines-Agency

Great post Num.

Correction- Craig Collard, Director at Sierra Oncology bought 13,500 Shares in Sierra at 23.03 dollars for 310,863 dollars.(purchased over two days).

Sorry for link problem
Purchase was 128,542.95 dollars.

https://stocktipstips.substack.com/

Purchased after hours yesterday.

Perhaps Sierra are going to announce more SRA 737 news. Interesting to see how Sierra’s share price performs this afternoon.

Guess we will find out soon as they have stated that toxicity studies will be completed by end of December?

Celtic Can’ t see toxicity being a problem -if it was why embark on expensive capsule production?

Great posts RMM. With Peel Hunt now very involved, I expect Tim and John to be under a lot of pressure to deliver CTAs for SDC 1801 and 1802 much quicker than the current plan. The time for drift is over. Announcement along these lines at the AGM would set us up nicely for the New Year.

And your just another dog of a person on aim.

Spurs - most comments on here are based on pure conjecture as we do not know what is going on behind the scene. That should not stop us from putting forward possible scenarios for the future. A plan is only a plan until something happens to change it. Only the science is set out in black and white. And that is the important thing.

Just my view - Pfizer’s is a Jak1/TYK2 inhibitor which I believe means it is mainly based on Jak1 but with a smaller combination of TYK2. This may mean that there is higher toxicity and would require a black box warning. Sareum’s SDC 1801 and 1802 are mainly made up of TYK2 with a small addition of Jak1. Not a scientist so please correct me if this is incorrect.

I wouldn’t argue with that Kendyboy. The reason for the delay - to suddenly change to capsule form - just does not add up.

https://pubmed.ncbi.nlm.nih.gov/34719635/

Silver - Your “only possible news list’’ is a very exciting list and as you say these might happen in the next 6 months or so.

https://newsfilter.io/a/557777e28ec9b670fd7b70730dff5233

Just out. Sierra submits Form Effect ( notice of effectiveness filed with SEC). Prospectus process up and running. Lots of information to run through.

Dilley’s speaking at the Jeffries Conference in London on Thursday at 8.00am. He will be looking for investors to support his 200,000,000 Prospectus. He will have to mention SRA 737 as it is included in the Prospectus plans. Await with interest.

https://newsfilter.io/a/779f37b6b8c1791f78f41bc82b9240d6

Note that Oric Pharmaceuticals has appointed Angie You to its Board of Directors. She formerly served as chief business and strategy officer at Sierra Oncology where she led the company’s strategic and transactional business and commercial efforts including its pipeline through acquisition and licensing of several product assets. (Anyone recall her being involved with SRA 737 licensing?)
Oric pharmaceuticals focuses on overcoming resistance in Cancer. It’s lead product Oric-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor which has been linked to resistance in multiple classes of cancer therapies across a wide variety of Solid Tumours.

Solid tumours are SRA 737s main target so Oric101 might turn out to be ideal for including ii in combinations with SRA 737 and other molecules such as keytruda.

Zylo - also been taking a close look at the share price. It’s more than holding its own even though the raise is seeking $200,000,000. I think we know why.

Steady - we are being trolled because whoever is behind it knows that Sareum presents a once in a lifetime opportunity to make large profits. But as they are obsessed with greed they want to make even more profit by forcing the current share price down rather than buy in at what is already a price that does not reflect current value. They will have to buy back in at sometime and I hope they get caught out big time by a sudden big news announcement. It would be well deserved.